RT Journal Article ID 67c567105161e7ef A1 Kanwar, Navjot A1 Sinha, Vivek Ranjan T1 In Situ Forming Depot as Sustained-Release Drug Delivery Systems JF Critical Reviews™ in Therapeutic Drug Carrier Systems JO CRT YR 2019 FD 2018-11-29 VO 36 IS 2 SP 93 OP 136 K1 controlled release K1 PLGA K1 NMP K1 syringeability K1 Regel technology AB In situ forming systems can serve as promising alternative to existing long acting injectables like disperse systems and microspheres, owing to their biocompatibility, stability, ease of administration and scale up. Microspheres based on long-acting parenteral systems pose challenges in scaling up and process changes with the drug and polymer selected. In situ gelling systems are having low viscosity which is very conducive during various manufacturing unit operations and passing the formulation through hypodermic needle with lower applied pressure. Different mechanisms such as physical or physiological stimuli and cross linking reactions are involved in the gelling of in situ forming systems at the site of injection. Drug release from in situ forming systems can be altered according to the need by using different polymers, lipids and fatty acids. In situ forming systems can be evaluated by sol-gel transition time, temperature and pH, rheology, gel strength, texture analysis, syringeability and injectability. The present paper is an overview of the various in situ gelling polymers and their application in the preparation of depot formulations. Numerous products based on in situ forming systems such as Eligard®, Atridox® are available in market. PB Begell House LK https://www.dl.begellhouse.com/journals/3667c4ae6e8fd136,389e9bee07f1e347,67c567105161e7ef.html